Dual HER2 blockade with trastuzumab and pertuzumab (TP) combined with chemotherapy is the standard neoadjuvant therapy for early‐stage or locally advanced HER2‐positive breast cancer. The gene discussed is ERBB2; the disease is breast cancer.